What's New At Isto.

New Fibrant line changes the game of fiber grafting

The acquisition of TheraCell, Inc. will expand access for two best-in-class product portfolios and build upon Isto’s continued commitment to putting patients and their surgical champions first.

MedTech Outlook has named Isto Biologics as a 2020 Top 10 Orthopedic Solution Provider

Isto Biologics falls under a list of designated businesses providing essential services that shall continue to operate during this two-week time period. Within this time frame, Isto has measures in place to ensure that we can ship products to other parts of the country, and around the world as needed. Under the guidance from the State of Massachusetts as well as the Department of Public Health, Isto will comply with all social distancing protocols.

As COVID-19 continues to impact our communities on a local and global scale, we want to take a moment to share the changes we are making to ensure the support of both our Isto customers and employees.

Isto Biologics, a leading biologics and regenerative medicine company offering advanced solutions in bone repair and cell-based therapies, announced today the addition of Influx Demineralized Bone Matrix Putty to their existing portfolio of bone healing and autologous cellular solutions.

Isto Biologics, a leading biologics and regenerative medicine company offering advanced solutions in bone repair and cell-based therapies, announced today the addition of InfluxTM Demineralized Cortical Bone Fibers to their existing portfolio of bone healing and autologous cellular solutions.

We’re proud to announce the next installment of our Regenerative Medicine Educational Series. Our semi-annual peer-to-peer events explore physician-focused topics regarding the advancements in biologics and autologous therapy in medicine.

Isto Biologics’ Medical Education team recently supported a biologics Hospital-Based Observation Preceptorship led by Dr. Edgardo Rodriguez, DPM.

Isto Holdings, the parent company of St. Louis-based Isto Biologics has acquired Progenicare, a national medical sales and service company.

Isto Biologics’ Medical Education team recently supported a cadaver lab led by Dr. Blake Johnson, Medical Director at CDI – Twin Cities MN.

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis with $1.5 billion of assets under management, announced today that it has acquired the commercial operations of ISTO Technologies (ISTO) headquartered in St. Louis, MO.

ISTO Technologies, Inc., a privately-held orthobiologic regenerative medicine company, announces the publication of positive clinical results reported for InQu® Bone Graft Extender & Substitute in a comparative study of two bone graft materials in posterolateral lumbar fusion.